A key reason why many ASX fund managers underperformed last financial year

One particular stock agonised many fund managers in FY25.

| More on:
Broker looking at the share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

As we roll into a new financial year, investors and fund managers will be reflecting on their FY25.

The past financial year proved to be a standout for many S&P/ASX 200 Index (ASX: XJO) companies. 

In FY25, the ASX 200 Index rose 10%. According to Vanguard, this is slightly above the Australian share market's long-term average of 9.2% per annum. 

Strong performance came from companies across a broad range of sectors. 

In the technology space, family location app Life 360 Inc (ASX: 360) gained an impressive 101% in FY25. 

Within the mining sector, Evolution Mining Ltd (ASX: EVN) lifted a staggering 129% over the 12-month period. 

Meanwhile, biotech giant Telix Pharmaceutics Ltd (ASX: TLX) rose 35%.  

Investment conglomerate Washington H Soul Pattinson and Company Ltd (ASX: SOL) also had a solid 12 months, sitting 28% higher. 

Telecommunications company Telstra Ltd (ASX: TLS) also had a standout period, rising 35%. 

Even supermarket giant Coles Group Ltd (ASX: COL) gained 23%.

Measuring performance

The ASX 200 Index is a common benchmark for many Australian fund managers to measure their performance each financial year. 

Those who included the aforementioned ASX 200 companies in their portfolios are more likely to have beaten the index in FY25. 

However, there's one standout ASX 200 company (yet to be mentioned) that fund managers are less likely to have taken a material position in during FY25. 

That company is the banking giant Commonwealth Bank of Australia (ASX: CBA). 

CBA shares are up 47% over the past 12 months. They are also the largest company in the ASX 200, with a market capitalisation in excess of $300 billion. 

CBA shares make up around 12% of the index. For reference, the next largest company, BHP Ltd (ASX: BHP), accounts for around 7% of the index.

Therefore, CBA's 12 month performance has had a significant impact on the ASX 200 Index's returns. This is problematic for fund managers who are underweight CBA shares.

Why are fund managers likely to be underweight CBA?

Over the past couple of financial years, a growing number of investment professionals have warned that CBA shares are materially overvalued. 

With CBA shares now trading at a price-to-earnings ratio (P/E) of above 30, it's an easy case to make. 

Last week, the Australian Financial Review reported:

CBA set another world record [last] week by becoming the first developed market lender to trade on a price to earnings multiple of 30 times – almost double the historic average of 16 times as far back to 1996. There is no other bank in the world that is valued at more than 20 times its earnings.

Broker Macquarie Group Ltd (ASX: MQG) currently has a price target of $105 on the company. 

For valuation reasons, the majority of active fund managers were underweight CBA shares last financial year. For example, Wilson Asset Management lists CBA as one of its top five underweight positions in its WAM Leaders (ASX: WLE) fund. 

As reported by the Australian Financial Review, Regal Partners investment director Charlie Aitken told clients CBA was "the biggest single-stock bubble [he's] seen in 30 years of being at the coalface".

Foolish Takeaway

In FY25, the majority of active fund managers avoided buying CBA shares for valuation reasons. Now, as they review their performance, they see the cost of missing out on significant gains made by the ASX 200's biggest company.

Motley Fool contributor Laura Stewart has positions in Wam Leaders and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Life360, Macquarie Group, Telix Pharmaceuticals, and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia has positions in and has recommended Coles Group, Macquarie Group, Telstra Group, and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia has recommended BHP Group and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Three small children reach up to hold a toy rocket high above their heads in a green field with a blue sky above them.
Growth Shares

These 4 ASX 200 stocks could jump another 70% to 80% in 2026

These stocks are expected to rocket higher.

Read more »

Two excited woman pointing out a bargain opportunity on a laptop.
Share Gainers

3 ASX 200 stocks jumping higher in this week's falling market

Investors shrugged off the broader market retrace and piled into these three ASX 200 stocks this week.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why EOS, Lotus Resources, REA, and Web Travel shares are dropping today

These shares are ending the week deep in the red. But why?

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Brambles, HMC Capital, ResMed, and Rio Tinto shares are rising today

These shares are avoiding the selloff and are pushing higher on Friday.

Read more »

A woman looks shocked as she drinks a coffee while reading the paper.
Share Fallers

Why is the Web Travel share price crashing 41% on Friday?

ASX investors are pummelling Web Travel shares today. But why?

Read more »

A man looking at his laptop and thinking.
Materials Shares

Rio Tinto shares charge higher after Glencore merger collapses

The parties couldn't come to an agreement.

Read more »

a group of doctors and medical staff in uniform high five in celebration in a hospital setting
Share Market News

Neuren Pharmaceuticals kicks off Phase 3 trial in rare syndrome

Neuren Pharmaceuticals shares are on watch after dosing began in its key Phase 3 trial for Phelan-McDermid syndrome.

Read more »